UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1426-1
Program Prior Authorization/Notification
Medication Jesduvroq® (daprodustat)
P&T Approval Date 1/2024
Effective Date 4/1/2024
1. Background:
Jesduvroq (daprodustat) is a hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor
indicated for the treatment of anemia due to chronic kidney disease in adults who have been
receiving dialysis for at least four months.
Limitations of Use
• Jesduvroq has not been shown to improve quality of life, fatigue, or patient well-being.
• Jesduvroq is not indicated for use as a substitute for transfusion in patients requiring
immediate correction of anemia or in patients not on dialysis.
2. Coverage Criteriaa:
A. Initial Authorization
1. Jesduvroq will be approved based on both of the following criteria:
a. Diagnosis of anemia due to chronic kidney disease (CKD)
-AND-
b. Patient has been receiving dialysis for at least four months
Authorization will be issued for 12 months.
B. Reauthorization
1. Jesduvroq will be approved based on the following criterion:
a. Documentation of positive clinical response to Jesduvroq therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
© 2024 UnitedHealthcare Services, Inc.
1
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class
4. References:
1. Jesduvroq [package insert]. Durham, NC: GlaxoSmithKline; August 2023.
Program Prior Authorization/Notification - Jesduvroq (daprodustat)
Change Control
1/2024 New program.
© 2024 UnitedHealthcare Services, Inc.
2